MYLK3 Knockout Raji Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Raji B lymphocyte line, in which the MYLK3 gene has been disrupted to create a loss-of-function model. This polyclonal knockout product provides a heterogeneous pool of cells carrying targeted gene disruption, suitable for studying MYLK3 function without the need for single-cell cloning.
The Raji host cell line is a human B lymphocyte suspension line established from a Burkitt’s lymphoma patient. It is Epstein-Barr virus (EBV)-positive and widely employed in immunology and cancer research for its roles in antibody production, antigen presentation, and immune response. Raji cells grow in suspension and maintain a lymphoblastoid morphology, offering a readily transfectable and robust in vitro system.
MYLK3 encodes a cardiac-specific myosin light chain kinase that is activated by calcium-bound calmodulin and primarily phosphorylates the myosin regulatory light chain 2 (MYL2). This phosphorylation enhances actin-myosin cross-bridge cycling and promotes sarcomere organization, directly regulating cardiac muscle contraction. Upstream regulators include beta-adrenergic receptor agonists, Protein Kinase A, and Protein Kinase C, while Calmodulin, Myosin heavy chain, Actin, and Tropomyosin are key interacting factors. Representative pathway components encompass TNNT2 and TNNI3, positioning MYLK3 within the cardiac muscle contraction and calcium signaling pathways.
Although MYLK3 is cardiac-specific, its targeted disruption in Raji B lymphocytes provides a unique platform to investigate potential non-canonical roles of this kinase outside the cardiac context. The Raji cell background, with its well-characterized signaling networks and suspension growth, allows researchers to examine whether MYLK3 influences cytoskeletal dynamics, adhesion-related signaling, or other processes in B cells that may have been masked by cardiac-specific expression. This knockout model thus aids in dissecting context-dependent functions of myosin light chain kinase activity.
Researchers can employ this knockout model in a variety of experimental settings, including Western blotting for phosphorylated MYL2 to assess kinase activity, immunofluorescence microscopy to visualize potential cytoskeletal changes, calcium imaging to monitor signaling, and RNA-seq to profile transcriptional alterations. It is suitable for drug screening efforts targeting heart failure, cardiomyopathy disease modeling using complementary systems, and gene function studies in non-cardiac B lymphocytes. For further information, please contact Ascent Research.
